$40M NIH Award Expands Groundbreaking Alzheimer’s Study; Recruitment to Begin Soon

$40M NIH Award Expands Groundbreaking Alzheimer’s Study; Recruitment to Begin Soon
The National Institutes of Health's recent $40 million award over the next five years will provide a new stage of research for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), an NIH public-private partnership. The ADNI is supported by the Foundation for the National Institutes of Health (FNIH), which anticipates $20 million in contributions from the private sector. The two awards will fund ADNI3, an extension of the global research effort that supports the investigation and development of treatments that slow or stop the progression of Alzheimer's disease. Recruitment of hundreds of new volunteers for ADNI3 is planned to begin this fall. ADNI3 is a five-year extension of the ADNI study, which is now on its 12th year. The multi-site, longitudinal study assesses clinical, imaging, genetic, and biospecimen biomarkers through the process of normal aging to early mild cognitive impairment (EMCI), to late mild cognitive impairment (LMCI), to dementia or Alzheimer's. Using established methods for imaging and biomarker collection and analysis, ADNI facilitates a way for scientists to conduct research and share compatible data with other scientists around the globe. ADNI3 will use cutting-edge methods in brain imaging to speed clinical trials by offering investigators the biomarkers required to detect the onset of Alzheimer's and track the progression of the disease. The study matches clinical and cognitive testing changes with Alzheimer’s-related changes detected in the volunteers' blood, cerebrospinal fluid, and DNA. Brain scans are used to detect brai
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *